2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Pediatric, Young Adult
PAPER

4890 Septin11 and Septin8 play critical and overlapping roles in murine hematopoietic stem cell function

Safa Mohamad, PhD, Chad E. Harris, MS2, David A. Williams, MD3
1 Boston Children's Hospital, Boston, Massachusetts, United States
2 Boston Children's Hospital, Boston, Massachusetts, United States
3 Boston Children's Hospital, Boston, Massachusetts, United States

Septins are highly conserved GTP binding proteins that are considered the fourth component of the cytoskeleton and have been implicated in hematopoietic stem and progenitor cell (HSPC) polarity. They are grouped into subfamilies based on sequence similarity and in yeast Septins within the same subfamily can subserve some overlapping functions. In poor prognosis infant Mixed-Lineage Leukemia (MLL) fusion leukemias, SEPTIN6 subfamily members are the most frequent fusion partners with the MLL gene although their function in leukemogenesis has not been defined. We have described mutations in SEPTIN6 associated with congenital neutropenia and development of infant myelodysplastic syndrome (MDS) associated with premature HSPC senescence. Here we investigate Septin11 belonging to the Septin6 subfamily that is highly expressed in HSPCs.

Knockdown of Septin11 in murine HSPC using a lentivirus vector (LVV) shmiR targeting Septin11 (Septin11 shmiR LVV) resulted in reduced progenitor growth with defects in both CFU-GM (Control:91.7+/-2.9 vs Sept11 shmiR:18.7+/- 3.1; mean+/-SD, N=3, p<0.0001) and BFU-E (Control:18.3+/-10.4 vs Sept11 shmiR:4+/-1; p<0.05) colonies. Competitive repopulation assays validated that Septin11 shmiR LVV transduced LSK cells were outcompeted by control cells as demonstrated at 4 months post-engraftment in peripheral blood (PB) (Control:73.9+/-26.1 vs Sept11 shmiR:15.3+/-20.4; %GFP+ chimerism, mean+/-SD, N=6-8 mice, p<0.001); and bone marrow (BM) (Control:73.6+/-28.8 vs Sept11 shmiR:17.2+/-22.5; p<0.005). Secondary transplants showed an unexpected improvement of the engraftment defect in the Septin11 LVV shmiR group, with recovery observed in PB (Control:95.5+/-8.5 vs Sept11 shmiR:92.8+/-11; N=10 mice) and BM (EV Control:88.7+/-20.2 vs Sept11 shmiR:88.5+/-13.2; %GFP+ chimerism at 4 months). Analysis revealed a concurrent increase in expression of another Septin6 subgroup member, Septin8.

To more precisely define the function of Septin11 in specific HSPC sub-populations, we performed knockdown in purified FACS-sorted cells. Transplantation of transduced LT-HSC or ST-HSC led to a significant decrease in multilineage engraftment demonstrated in PB and BM (LT-HSC: Control:76.7+/16.2 vs Sept11 shmiR:23.2+/-20.9; ST-HSC: Control:83.1+/12.6 vs Sept11 shmiR:31.7+/-25.9; %GFP+ chimerism at 4 months, N=7-9 mice, p<0.0001), while transduced MPP showed no significant defect in engraftment in PB or BM (Control:58.7+/20.3 vs Sept11 shmiR:48.4+/-15.7; N=8-10 mice). Septin8 mRNA expression was upregulated 2.8+/-0.7-fold in transplanted, transduced MPP cells with no change in expression in transplanted LT-HSC and reduced expression in transplanted ST-HSC. These data demonstrated a correlation between defects in engraftment in Septin11 knockdown and induction of Septin8 implying functional redundancy between Septin8 and Septin11.

To confirm overlapping roles between Septin8 and Septin11 in hematopoiesis we constructed a LVV containing a shmiR against Septin11 and simultaneously expressing the Septin8 cDNA. Knockdown of Septin11 and concurrent overexpression of Septin8 led to rescue of the defective progenitor growth seen with reduced Septin11 expression alone (Control:174.7+/-3.2 vs Sept11 shmiR:135.3+/-18.5 (p<0.0001) vs Sept11 shmiR+ Sept8 cDNA:235+/-14.7 (p=NS)). Consistent with this data, competitive repopulation assays demonstrated that concurrent transgenic expression of Septin8 partially rescued the engraftment defect of Septin11 knockdown up to 4 months post-engraftment in PB (Control:74.5+/-27.9 vs Sept11 shmiR+ Sept8 cDNA:50.2+/-36.2; %GFP+ chimerism, N=7-10 mice, p=NS).

To examine the potential mechanism of Septin8 mitigation of reduced Septin11 expression, we examined multiple HSPC biological properties. These revealed a significant increase in senescent cells accompanied by an increase in early apoptosis in LSK cells with knockdown of Septin11. However, the Septin11 LVV shmiR with concurrent Septin8 cDNA expression mitigated this senescence defect (Fold Change: Control:1+/-0 vs Sept11 shmiR:1.9+/-0.2 vs Sept11 shmiR+ Sept8 cDNA:0.9+/-0.1, β-galactosidase+ cells; N=3).

Here we demonstrate functional redundancy in the Septin6 subfamily of proteins in the HSPC compartment. Septin6 genes are often implicated in MLL fusion leukemias and recently found to be mutated in MDS. Understanding redundancy and functional roles of Septin family members in HSPC may provide new approaches to vulnerabilities in MDS and leukemias.

Safa Mohamad, PhD: No relevant conflicts of interest to declare.